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Background
Despite the expanding research base on the genetic testing
process, limited insight exists on how personal under-
standings of hereditary cancer as well as situational
and contextual factors influence an individual’s decision-
making prior to and following predictive testing for her-
editary non-polyposis colorectal cancer (HNPCC). The
failure of existing scales to detect psychosocial and beha-
vioral difficulties in this population has led researchers to
question the adequate sensitivity of these instruments.
The purpose of this study was to develop and validate
measures for evaluating the preparedness for and experi-
ences during and following predictive testing for HNPCC.
Methods
A grounded theory study of individuals from families
with a confirmed HNPCC presence provided the data
for item generation and scale construction. The Heredi-
tary Diseases and Genetic Testing (HD-GT) scale con-
sists of 8 scales designed to measure acceptance of
hereditary-based diseases and engagement in the genetic
testing process. Scale readability and content validity
were assessed prior to data collection. The HD-GT scale
was administered to a sample of individuals (N = 242;
141 carriers and 101 non-carriers) from families with a
M S H 2 ,M L H 1o rM S H 6m u t a t i o n .T h eM u l t i t r a i tA n a -
lysis Program-Revised (MAP-R) evaluated data quality,
and scoring and scaling assumptions.
Results
Preliminary findings support the logic of the psycho-
metric structure of the HD-GT. The rating scale steps
(0 to 4) seem to have meaningful divisions as evidenced
by the response spread. The MAP-R analysis supported
item-to-scale appropriateness, scale reliability (≥ .75)
and pattern of scale correlations (internal consistency
scores significantly higher than intrascale correlations).
S t u d yf i n d i n g ss u g g e s tt h a tt h ef a m i l yh i s t o r yo fc a n c e r
does have a significant impact on decision-making
regarding genetic testing. There are also indications that
individuals place high value on having all potentially at-
risk family members participate in genetic testing, but
are often challenged trying to convince them to accept
the need for testing.
Conclusions
The HD-GT scale represents an initial effort to evaluate
personal, situational and contextual factors influencing
genetic testing decision-making. Study findings suggest
that the subscales appear to be sensitive enough to mea-
sure the wide-range of psychosocial and behavioral
implications of genetic testin g .F u r t h e r ,f i n d i n g sh a v e
important implications for health care providers. If pro-
viders are to work effectively with HNPCC families they
must have the appropriate knowledge, education and
skills to recognize the features of HNPCC, take thor-
ough client and family histories, provide support and
coordinate care for these individuals.
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